Stenmax Pharmaceuticals Private Limited
About Stenmax Pharmaceuticals Private Limited
Data last updated:
Stenmax Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the manufacturing segment of the chemicals sector. It was incorporated on 26 November 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24290DL2019PTC358063.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Amresh Kumar Sinha and Rajiv Kumar Singh.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at H. No. 32 Kh No. 18/3 Nangli Vihar, New Delhi, Delhi, India – 110043.
As per the financials filed for FY 2025, the company reported a revenue of ₹5.13 Lakh, a decline of 16% compared to the previous year. For the same year it recorded a net loss of ₹2,137 (net margin -0.4%) and EBITDA of ₹12,292 (EBITDA margin 2.4%). Revenue has grown at a compounded annual rate (CAGR) of 1% over three years and 10% over five years.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressH. No. 32 Kh No. 18/3 Nangli Vihar, New Delhi, Delhi, India – 110043
- IndustryChemicals, Manufacturing, Other Chemical Product
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Stenmax Pharmaceuticals Private Limited
The main business activity of Stenmax Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Stenmax Pharmaceuticals Private Limited FY 2025 filings available
Stenmax Pharmaceuticals Private Limited reported revenue of ₹5.13 Lakh (down 16% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Stenmax Pharmaceuticals Private Limited
Revenue fell 16% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 10%. EBITDA fell 28% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Stenmax Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹12,292 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹2,137 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Stenmax Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 2.4% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -0.4% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Stenmax Pharmaceuticals are in the company report.
Financial statements from FY 2020
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Stenmax Pharmaceuticals Private Limited
Stenmax Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Pcag Pharmaceuticals Private Limited | ₹5.17 Lakh (FY 2024) | •••• | •••• | •••• | Delhi, India | |
| Idm Pharmaceuticals Private Limited | ₹5.17 Lakh (FY 2024) | •••• | •••• | •••• | Ponneri, Tamil Nadu, India | |
| Indova Pharmaceuticals Private Limited | ₹5.17 Lakh (FY 2024) | •••• | •••• | •••• | Pune, Maharashtra, India | |
| Kibozen Pharmaceuticals Private Limited | ₹5.16 Lakh (FY 2025) | •••• | •••• | 0.0% | •••• | Bulandshahr, Uttar Pradesh, India |
| Terveks Pharmaceuticals Private Limited | ₹5.14 Lakh (FY 2025) | •••• | •••• | -52.0% | •••• | Jamshedpur, Jharkhand, India |
| Stenmax Pharmaceuticals Private Limited this company | ₹5.13 Lakh (FY 2025) | •••• | •••• | -16.0% | •••• | New Delhi, Delhi, India |
| Immanence Pharmaceuticals Private Limited | ₹5.13 Lakh (FY 2024) | •••• | •••• | -26.0% | •••• | Badlapur, Maharashtra, India |
| Dione Pharmaceuticals Private Limited | ₹5.12 Lakh (FY 2025) | •••• | •••• | 7.0% | •••• | Bilaspur, Chhattisgarh, India |
| RSP Pharmaceuticals Private Limited | ₹5.12 Lakh (FY 2024) | •••• | •••• | -11.0% | •••• | Laheriasarai, Bihar, India |
| Drima Pharmaceuticals Private Limited | ₹5.1 Lakh (FY 2024) | •••• | •••• | -25.0% | •••• | Mumbai, Maharashtra, India |
| Procter Pharmaceuticals Private Limited | ₹5.08 Lakh (FY 2021) | •••• | •••• | -35.0% | •••• | Dehradun, Uttarakhand, India |
Peers are the five companies nearest above and the five nearest below Stenmax Pharmaceuticals by revenue in the Pharma industry (Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Stenmax Pharmaceuticals Private Limited
Stenmax Pharmaceuticals has 4 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Amresh Kumar Sinha | Director | 16 Dec 2023 | 2 Years 9 Months | Current |
| Rajiv Kumar Singh | Director | 26 Nov 2019 | 6 Years 10 Months | Current |
| Rakesh Kumar Thakur | Director | 26 Nov 2019 | 6 Years 10 Months | Current |
| Sanjeev Kumar Das | Director | 13 Jan 2022 | 4 Years 8 Months | Current |
Ownership and Shareholding of Stenmax Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Stenmax Pharmaceuticals Private Limited
Stenmax Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Stenmax Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Stenmax Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Stenmax Pharmaceuticals Private Limited
Stenmax Pharmaceuticals Private Limited has 4 board changes on record since 2019: 4 appointments. The latest: Amresh Kumar Sinha was appointed as Director on 16 Dec 2023.
Credit Ratings, Litigation & Regulatory Alerts for Stenmax Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Stenmax Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Stenmax Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Stenmax Pharmaceuticals Private Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Stenmax Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stenmax Pharmaceuticals Private Limited
Stenmax Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in manufacturing, within the chemicals industry. It was incorporated on 26 November 2019 (7+ years old) and is registered under CIN U24290DL2019PTC358063.
Stenmax Pharmaceuticals reported revenue of ₹5.13 Lakh for FY 2025 (down 16% YoY).
Stenmax Pharmaceuticals has 4 current directors:
- Amresh Kumar Sinha - Director
- Rajiv Kumar Singh - Director
- Rakesh Kumar Thakur - Director
- Sanjeev Kumar Das - Director
Stenmax Pharmaceuticals reported a net loss of ₹2,137 (net margin -0.4%) and EBITDA of ₹12,292 (EBITDA margin 2.4%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Stenmax Pharmaceuticals is -1% over three years and 10% over five years. In the latest year (FY 2025) revenue fell 16%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Stenmax Pharmaceuticals is U24290DL2019PTC358063. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Stenmax Pharmaceuticals was incorporated on 26 November 2019, making it 7+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Stenmax Pharmaceuticals by revenue are Pcag Pharmaceuticals Private Limited, Idm Pharmaceuticals Private Limited, Indova Pharmaceuticals Private Limited, Kibozen Pharmaceuticals Private Limited, Terveks Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharmaceuticals).
Amresh Kumar Sinha was appointed as Director on 16 Dec 2023. Sanjeev Kumar Das was appointed as Director on 13 Jan 2022. Rajiv Kumar Singh was appointed as Director on 26 Nov 2019. Stenmax Pharmaceuticals has 4 board changes on record in total.
The registered office of Stenmax Pharmaceuticals is at H. No. 32 Kh No. 183 Nangli Vihar, New Delhi, Delhi, India – 110043.
Stenmax Pharmaceuticals has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh.